LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Lista de Ações・Cogent Biosciences Inc

Cogent Biosciences Inc

Fechado

36.08 -2.09

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

35.9

Máximo

36.47

Indicadores-chave
By Trading Economics
Rendimento	-22M -102M
EPS	-0.5
Funcionários	258
EBITDA	-30M -109M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+42.53% upside

Dividendos
By Dow Jones
Próximos Ganhos	5 de mai. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	140M 5.7B
Abertura anterior	38.17
Fecho anterior	36.08

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

4.88 / 5.87 Suporte e Resistência

Cogent Biosciences Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mar. de 2026, 17:33 UTC

Notícias Principais

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 de mar. de 2026, 17:00 UTC

Notícias Principais

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 de mar. de 2026, 16:03 UTC

Notícias Principais

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 de mar. de 2026, 14:50 UTC

Grandes Movimentos do Mercado

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 de mar. de 2026, 14:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 de mar. de 2026, 14:29 UTC

Notícias Principais

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 de mar. de 2026, 14:16 UTC

Notícias Principais

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 19:16 UTC

Conversa de Mercado

Notícias Principais

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 de mar. de 2026, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 de mar. de 2026, 19:04 UTC

Conversa de Mercado

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 de mar. de 2026, 19:03 UTC

Conversa de Mercado

Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 19:02 UTC

Conversa de Mercado

Notícias Principais

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 de mar. de 2026, 18:12 UTC

Conversa de Mercado

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 de mar. de 2026, 17:36 UTC

Notícias Principais

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 de mar. de 2026, 17:34 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 de mar. de 2026, 17:29 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 de mar. de 2026, 16:38 UTC

Conversa de Mercado

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 de mar. de 2026, 16:32 UTC

Conversa de Mercado

Notícias Principais

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 de mar. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 15:43 UTC

Conversa de Mercado

Notícias Principais

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 de mar. de 2026, 14:36 UTC

Conversa de Mercado

Notícias Principais

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 de mar. de 2026, 14:26 UTC

Conversa de Mercado

Notícias Principais

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 de mar. de 2026, 14:14 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 14:14 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

Comparação entre Pares

Variação de preço

Cogent Biosciences Inc Previsão

Preço-alvo

By TipRanks

42.53% parte superior

Previsão para 12 meses

Média 52.55 USD 42.53%

Máximo 64 USD

Mínimo 35 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

Comprar

Manter

Vender

Com base em 12 analistas que deram avaliações de ações para Cogent Biosciences Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

4.88 / 5.87Suporte e Resistência

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.